Viking Therapeutics traded as low as $31.00 and last traded at $30.97. 886,719 shares traded hands during trading, a decline of 77% from the average session volume of 3,895,525 shares. The stock ...

Viking Therapeutics (NASDAQ:VKTX – Free Report) had its target price lowered by Maxim Group from $120.00 to $70.00 in a research note issued to investors on Friday morning,Benzinga reports.

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Reasons to buy Viking Therapeutics now It's hard to overstate the commercial success of drugs that reduce appetites by acting on glucagon-like peptide-1 (GLP-1) receptors.

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against the other stocks. Wall Street's major indices kicked off the trading on a positive note ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an “intriguing potential blockbuster,” with its GLP ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have ...

Nearly a year ago, Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results from a clinical trial with an experimental weight loss ...

Viking Therapeutics reports quarterly losses of 32 cents per share, which missed the analyst consensus estimate for losses of 28 cents. Viking reports a net loss of $35.4 million in the fourth ...